These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Iron chelator differentially activates macrophage inflammatory protein-3alpha/CCL20 in immortalized and malignant human oral keratinocytes.
    Author: Lee SK, Lee J, Min SK, Won DH, Lee YM, Lim HD, Lee W, Pae HO, Chung HT, Jun CD, Lee SK, Kim EC.
    Journal: Arch Oral Biol; 2008 Sep; 53(9):801-9. PubMed ID: 18328460.
    Abstract:
    Macrophage inflammatory protein-3alpha (MIP-3alpha or CCL20) is an intriguing molecule in cancer immunotherapy, but MIP-3alpha expression and signalling are not well understood in oral cancer cells. We investigated CCL20 expression and signal transduction by treating immortalized human oral keratinocyte (IHOK) and oral cancer (HN4) cells with deferoxamine (DFO) and examined the mRNA expression of CCL20 using RT-PCR and ELISA. IHOK and HN4 cells treated with DFO showed increased mRNA and protein expression of CCL20, and the upregulation of DFO-induced CCL20 expression was higher in IHOK cells than in HN4 cells. Selective inhibitors of p38 and ERK1/2 abolished DFO-induced CCL20 expression in both IHOK and HN12 cells, and p38 and ERK1/2 inhibitors prevented DFO-induced degradation of I-kappaB and NF-kappaB activation. Activation of c-fos and c-jun also occurred following DFO treatment in IHOK and HN4 cells. Collectively, these results suggest that DFO-induced MIP-3alpha, which is involved in the MAP kinase, c-fos, c-jun, and NF-kappaB pathways, may be an important mediator of the antitumour immune response in oral keratinocytes and warrants consideration as a target molecule for oral cancer treatment.
    [Abstract] [Full Text] [Related] [New Search]